Dr. Ranee Mehra, M.D.
Medical Oncology (Medical Oncology Physician)
1550 Orleans St, Crb Ii 5m.43
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 161
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D0082358
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Maryland Medical Center Baltimore, MD
- Luminis Health Anne Arundel Medical Center, Inc Annapolis, MD
Medical groups
- University of Maryland Oncology Associates PA (62 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 161
- Services billed
- 575
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 152 | 75 |
| Established patient office or other outpatient visit, 40-54 minutes | 128 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 42 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Baltimore, MD | 29 |
| Ondansetron Hcl Other prescribers in Baltimore, MD | 28 |
| Prochlorperazine Maleate Other prescribers in Baltimore, MD | 27 |
| Oxycodone Hcl Other prescribers in Baltimore, MD | 16 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Baltimore, MD | 13 |
| Tagrisso (osimertinib mesylate) | 12 |
| Eliquis (apixaban) Other prescribers in Baltimore, MD | 11 |
| Dexamethasone Other prescribers in Baltimore, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 10 payments worth $274 in total to this clinician.
| Daiichi Sankyo Inc. | $81.54 |
|---|---|
| Merck Sharp & Dohme LLC | $56.36 |
| Janssen Biotech, Inc. | $44.18 |
| Jazz Pharmaceuticals Inc. | $33.57 |
| Syndax Pharmaceuticals, Inc. | $24.71 |
| Caris Mpi, Inc. | $17.33 |
| Servier Pharmaceuticals LLC | $16.12 |
| Food and Beverage | $274 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $1,124,332 in research payments for these studies, mostly to the institutions running them.
- Expanded Access request for Tarlatamab to treat a 45 y.o. Female Patient with DLL3+ High grade Neuroendocrine Tumor of the Lung
Amgen Inc. - Study name not reported
Iovance Biotherapeutics, Inc. - A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Janssen Research & Development, LLC - Study name not reported
Iovance Biotherapeutics, Inc. - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04420884 - SRF114-101
Coherus Oncology, Inc. - A phase 2 basket study of disitamab vedotin in adult subjects with previously treated locallyadvanced unresectable or metastatic solid tumors that express HER2
Pfizer Inc. - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Recruiting · NCT06064877 - A phase 2 study of ALX148 in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma
Merck Sharp & Dohme LLC - A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Nec…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.